LOGIN
THC/CBD oromucosal spray is not better than placebo for diabetic neuropathy over 12 weeks
September 2018
THC/CBD oromucosal spray is not better than placebo for diabetic neuropathy over 12 weeks
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: Depression is a major confounding factor
Diabetes Care. 2010 ;33(1):128-130. http://dx.doi.org/10.2337/dc09-1029Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
30 patients with chronic painful diabetic peripheral neuropathy were randomized to receive Sativex (tetrahydrocannabinol 27 mg/mL and cannabidiol 25 mg/mL) or placebo, titrated over 2 weeks and maintained for 10 weeks. The purpose of this study was to determine if Sativex treatment results in better Neuropathic Pain Scale (NPS), total pain score (TPS), McGill Pain and QOL, SF-36 Health Survey, and...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.